Opto Circuits (India) Ltd, a healthcare equipment manufacturer, said its subsidiary received a clearance from the US Food & Drug Administration (FDA) for its new modular patient monitoring system - eVision 9100.
The certification enables its unit Criticare Systems Inc to sell eVision 9100 in most parts of the world, particularly in the US, which is one of the largest markets for patient monitors. According to Global Markets Direct, the revenue for multi-parameter patient monitors is estimated to be around $2,249 million, it said in a regulatory filing.
On Monday, Opto Circuits shares ended 1% up at Rs282 on Bombay Stock Exchange, while the benchmark Sensex gained 1.9% to 18,560 points.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
